ThePeptide Examiner
Subscribe
Issue 001 · launching soon

The signal in peptide science, decoded weekly.

Independent editorial coverage of the peptides reshaping medicine — GLP-1s, healing peptides, longevity research. No hype. No dosing advice. Clear-eyed reporting with named sources and named reviewers.

Free. Weekly. No spam, ever.

Latest coverage

What we're watching this week.

All news →
Issue

Why we don't publish 'where to buy' articles for research peptides

Half the peptide content online is vendor marketing with a journalism veneer. Here's our editorial position, why we hold it, and what it costs us.

Apr 22, 20264 min read
FDA / policy

Compounded semaglutide is gone. Here's what patients should know.

The FDA's semaglutide shortage-resolved declaration ended 503A and 503B compounding discretion in 2025. A year later, the clinical consequences are landing.

Apr 20, 20265 min read
Research

Orforglipron hits Phase 3 endpoint. The oral GLP-1 heads for FDA submission.

Eli Lilly's small-molecule oral GLP-1 agonist showed clinically meaningful weight loss and glycemic control in the ATTAIN and ACHIEVE trial programs. A pill version of the category is closer than it looked even six months ago.

Apr 18, 20266 min read

GLP-1 Hub

Everything you need to think clearly about GLP-1s.

Provider comparisons, evidence reviews, and plain-English coverage of a category that changes every quarter.

GLP-1

Compare telehealth providers

Hims, Ro, Henry, Mochi, MEDVi — side by side, updated weekly.

GLP-1

The deep dive on retatrutide

28.7% weight loss in Phase 3. What we know, and what we don't.

GLP-1

Bloodwork before you start

The tests any responsible provider should run. What to push back on.

Independent editorial coverage of peptide science. Evidence-cited, dated, and editorially reviewed. Affiliate relationships with FDA-approved telehealth providers and vetted partners are clearly labeled inline on every page that contains them.

About the publication

Common questions

What readers ask before subscribing.

Who writes The Peptide Examiner?

An editorial team committed to fact-checking every claim against primary sources (PubMed, ClinicalTrials.gov, FDA.gov). We use editorial review today; a named medical reviewer is on our near-term roadmap. Every article carries a dated review timestamp.

What do you cover — and what don't you?

We cover GLP-1 drugs, regulatory actions, peptide research, and FDA updates. We do NOT publish dosing protocols, "where to buy" articles for research-use-only peptides, or first-person product endorsements. The brief is editorial journalism, not vendor marketing.

How do you make money?

Affiliate relationships with FDA-approved telehealth providers and vetted compounding pharmacies. Every affiliate link is labeled inline and at the top of the containing article. We only feature partners we have an active affiliate relationship with — if we can't monetize a vendor, they don't appear on the site. Affiliate revenue doesn't influence ratings.

Is the newsletter free?

Yes. The weekly issue is free forever. A paid tier may launch later with deeper data access (COA purity database, vendor price tracking), but the weekly editorial stays free.

Do you use AI to write articles?

Our news desk uses AI (Anthropic's Claude) to draft initial summaries from primary sources. Every draft passes deterministic quality gates and a human editor before publishing. Evergreen evidence explainers are human-written. Nothing hits the site without human review.

Who should NOT read this?

If you're looking for dosing advice, stack recommendations, or "which vendor should I buy from" shortcuts, this isn't the publication for you. We report evidence and regulatory status; clinical decisions belong with your clinician.